Laboratory Corporation of America

At the Personalized Medicine Conference this week, stakeholders historically at odds over lab test regulation said it is up to Congress to resolve the issue.

LabCorp will be able to develop and commercialize the test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.

The new assay simultaneously detects four viral targets in donated blood plasma in a single sample and can add value to the biologics development space.

Under the new agreement, physicians can order both thyroid biopsy analysis and molecular testing from Interpace, and LabCorp's Dianon Pathology, will be available to do biopsy analysis.

Quest will also have early access to Thermo Fisher's pipeline of novel platforms and assays to assist with development of Oncomine-branded solutions.

Increased consumer interest in prenatal health is also spurring use of carrier screening for genetic conditions.

The suit filed against the acting HHS secretary alleges that a flawed data collection process failed to establish market-based rates.

Several commercial NIPT providers in the US said they are planning to participate in the new program.

Smaller labs, hospital outreach labs, and labs servicing high numbers of elderly are thought to face the highest risks.

The biggest losers following the release of the preliminary PAMA rates may be Quest and LabCorp, analysts said today. 

Pages

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.